These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3546146)

  • 21. Increasing antibiotic dose decreases polymicrobial infection after hemorrhagic shock.
    Livingston DH; Malangoni MA
    Surg Gynecol Obstet; 1993 May; 176(5):418-22. PubMed ID: 8480263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of cefoxitin, cefotetan, and ampicillin/sulbactam as prophylaxis for polymicrobial infection in mice.
    Brook I
    Clin Infect Dis; 1995 Jun; 20 Suppl 2():S376-7. PubMed ID: 7548603
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of metronidazole on Escherichia coli in the presence of Bacteroides fragilis: an investigation in mice.
    Reznikov M; McDonald PJ
    Chemotherapy; 1983; 29(3):225-9. PubMed ID: 6347547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reciprocal synergy between Escherichia coli and Bacteroides fragilis in an intra-abdominal infection model.
    Rotstein OD; Kao J; Houston K
    J Med Microbiol; 1989 Aug; 29(4):269-76. PubMed ID: 2668529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A peritonitis model with low mortality and persisting intra-abdominal abscesses.
    Buyne OR; Bleichrodt RP; Verweij PE; Groenewoud HM; van Goor H; Hendriks T
    Int J Exp Pathol; 2006 Oct; 87(5):361-8. PubMed ID: 16965563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The spectrum of Escherichia coli--Bacteroides fragilis pathogenic synergy in an intraabdominal infection model.
    Rotstein OD; Kao J
    Can J Microbiol; 1988 Mar; 34(3):352-7. PubMed ID: 3046726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of prophylactic antibiotics upon mixed infections with Bacteroides fragilis.
    Brook I
    Surg Gynecol Obstet; 1987 Dec; 165(6):491-5. PubMed ID: 3317944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inactivation of cefuroxime and cefotaxime by Bacteroides fragilis in vitro, and its influence on the treatment of an experimental Escherichia coli/Bacteroides fragilis mixed infection.
    Beale AS; Gisby J
    J Antimicrob Chemother; 1989 Jul; 24(1):29-37. PubMed ID: 2674099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancement of survival from murine polymicrobial peritonitis with increased abdominal abscess formation.
    Cheadle WG; Hershman MJ; Mays B; Melton L; Polk HC
    J Surg Res; 1989 Aug; 47(2):120-3. PubMed ID: 2502684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistence of polymicrobial abscesses in the poorly controlled diabetic host.
    Bessman AN; Sapico FL; Tabatabai M; Montgomerie JZ
    Diabetes; 1986 Apr; 35(4):448-53. PubMed ID: 3514325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protective efficacy of immunization with capsular antigen against experimental infection with Bacteroides fragilis.
    Kasper DL; Onderdonk AB; Crabb J; Bartlett JG
    J Infect Dis; 1979 Nov; 140(5):724-31. PubMed ID: 528789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of pure or combined inocula of Escherichia coli and Bacteroides fragilis on the liver and related metabolism.
    Rink RD; Kaelin CR; Raque G; Trachtenberg LS; Fry DE
    Lab Invest; 1982 Mar; 46(3):282-7. PubMed ID: 7038296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative in vitro activities of ciprofloxacin, enoxacin, norfloxacin, ofloxacin and pefloxacin against Bacteroides fragilis and Clostridium difficile.
    Edlund C; Nord CE
    Scand J Infect Dis; 1986; 18(2):149-51. PubMed ID: 2939556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relative efficacy and critical interval of antimicrobial agents in experimental infections involving bacteroides fragilis.
    Bartlett JG; Dezfulian M; Joiner K
    Arch Surg; 1983 Feb; 118(2):181-4. PubMed ID: 6849635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune T cells prevent bacteroides fragilis abscesses.
    Shapiro ME; Onderdonk AB; Kasper DL; Finberg RW
    Curr Surg; 1983; 40(2):123-6. PubMed ID: 6602035
    [No Abstract]   [Full Text] [Related]  

  • 36. A soluble suppressor T cell factor protects against experimental intraabdominal abscesses.
    Zaleznik DF; Finberg RW; Shapiro ME; Onderdonk AB; Kasper DL
    J Clin Invest; 1985 Mar; 75(3):1023-7. PubMed ID: 2579976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response of a 'susceptible' Escherichia coli to metronidazole therapy: an investigation using experimental subcutaneous abscesses.
    Reznikov M; Hakendorf PH; Matthews DB
    Chemotherapy; 1985; 31(1):50-4. PubMed ID: 3882353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative efficacy of 10 antimicrobial agents in experimental infections with Bacteroides fragilis.
    Joiner K; Lowe B; Dzink J; Bartlett JG
    J Infect Dis; 1982 Apr; 145(4):561-8. PubMed ID: 7069236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative efficacy of ceftriaxone in experimental infections involving Bacteroides fragilis and Escherichia coli.
    Dezfulian M; Bitar RA; Bartlett JG
    Chemotherapy; 1993; 39(5):355-60. PubMed ID: 8370326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical pharmacology of ofloxacin: a new chemotherapeutic agent belonging to the gyrase inhibitor group].
    Verho M; Dagrosa EE; Malerczyk V
    Infection; 1986; 14 Suppl 1():S47-53. PubMed ID: 3007366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.